ANNUAL RESULTS: ANALYST PRESENTATION

FY22 Results 7th December 2022

Giulio Cerroni	Grant Nash
CEO	CFO

Nonregulated Disclaimer

This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certain information drawn from public sources does not purport to be comprehensive and has not been independently verified. It has been prepared and issued by and is the sole responsibility of the Company.

No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or in any revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice.

In particular, this presentation may contain certain forward-looking statements that are subject to the usual risk factors. Whilst the Company believes the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may be materially different owing to factors beyond the Company's control or with in the Company's control where, for example the Company decides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or other forward-looking statements, any assumptions underlying them, the future operations or the amount of any future income or loss.

The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of any services provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment in business to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

By attending the presentation or reading or accepting this document you agree to be bound by the foregoing limitations.

IXICO plc is incorporated in England with registered number 3131723 and registered address 15 Long Lane, London, EC1A 9PN.

2	PUBLIC © IXICO plc 2022

Driven By Our Purpose

3	PUBLIC © IXICO plc 2022

Our purpose drives our culture, our services and our strategy

Our purpose driven approach

To advance medicine and human health by turning medical imaging data

from clinical trials into clinically meaningful information

Our 4 "A" values

What we do

1. Innovate

2. Deploy and deliver

3. Value Insights

Our 'Precision in Neuroscience' strategy

1. Build

2. Innovate

3. Penetrate 4. Bridge

5. Enhance

4

PUBLIC © IXICO plc 2022

Advanced Analytics - Intelligent insights

• Neuroscience Specialists: Able to tailor services to each client's trial protocol requirements
• Track record of Innovation: Disease specific, AI driven quantitative imaging biomarker analysis.
• • Rapid expansion of proprietary AI driven analytical tools across adjacent therapeutic indications
  • LEAP - well-validated and published, patent-protected technology, pioneering fully-automated volumetry in clinical trials for more than a decade
  • IXIQ.Ai - next generation platform leveraging AI for a customisable brain segmentation, enabling high-quality analysis of regions previously not possible - powered by IXICO's R&D imaging database across CNS indications and data modalities
• Trusted: Functional core imaging lab operations to support global studies
• • 21 CFR11 & GCP compliant end-to-endTrialTracker imaging platform.
  • Approved partner. Successful delivery of multiple global studies, including world's largest PIII HD study

5	• Next generation TrialTracker imaging platform being developed

PUBLIC © IXICO plc 2022